We were pleased to read the recent article by Goni et al., entitled “Effectiveness and safety of rituximab across the four phenotypes of IgG4-related disease: a European multi-center cohort study of 115 patients,” published in the European Journal of Internal Medicine [1]. The authors deserve recognition for tackling a clinically significant and often overlooked question—whether rituximab (RTX) efficacy varies across IgG4-RD phenotypes. Their multi-center approach and careful phenotypic classification offer meaningful real-world insights that usefully supplement trial evidence.
